Choosing an equivalence limit for noninferiority or equivalence studies

被引:109
作者
Wiens, BL [1 ]
机构
[1] Amgen Inc, Dept Biostat, Thousand Oaks, CA 91320 USA
来源
CONTROLLED CLINICAL TRIALS | 2002年 / 23卷 / 01期
关键词
equivalence limit; active control; role of statistician; putative placebo;
D O I
10.1016/S0197-2456(01)00196-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Studies that compare treatments with the purpose of demonstrating that the treatments are similar require an a priori definition of an equivalence limit, how different the treatments can be before the difference is of concern. Defining such an equivalence limit is one of the most difficult aspects of planning the study. Three principles are proposed for setting such limits, depending on the objective of the study: a putative placebo calculation, an approach based on clinically important differences, and methods based on statistical properties. All methods will be useful for many studies, but the study objective should determine the Final choice of an equivalence limit. The statistician must play an integral role in determining the final equivalence limit. Advice is offered for helping the statistician participate in the decision on the equivalence limits. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:2 / 14
页数:13
相关论文
共 49 条
[1]  
[Anonymous], 1999, GUIDANCE IND CLIN DE
[2]   PROVING THE NULL HYPOTHESIS IN CLINICAL-TRIALS [J].
BLACKWELDER, WC .
CONTROLLED CLINICAL TRIALS, 1982, 3 (04) :345-353
[3]  
Bristol D R, 1996, J Biopharm Stat, V6, P319, DOI 10.1080/10543409608835146
[4]   A perspective on the regulation of the evaluation of new antithrombotic drugs [J].
Califf, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8B) :25P-35P
[5]  
Chuang-Stein C, 1999, DRUG INF J, V33, P1189, DOI 10.1177/009286159903300422
[6]   THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT [J].
COOK, RJ ;
SACKETT, DL .
BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :452-454
[7]  
Dunnett CW, 1996, STAT MED, V15, P1729
[8]  
Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO
[9]  
2-A
[10]   Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases [J].
Ellenberg, SS ;
Temple, R .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :464-470